<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066220</url>
  </required_header>
  <id_info>
    <org_study_id>SIOP PNET 5 MB</org_study_id>
    <secondary_id>2011-004868-30</secondary_id>
    <nct_id>NCT02066220</nct_id>
  </id_info>
  <brief_title>International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma</brief_title>
  <official_title>An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Kinderkrebsstiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study PNET 5 MB has been designed for children with medulloblastoma of standard risk
      (according to the risk-group definitions which have been used so far; e.g. in PNET 4). With
      the advent of biological parameters for stratification into clinical medulloblastoma trials,
      the ß-catenin status will be the only criterion according to which study patients will be
      assigned to either treatment arm PNET 5 MB - LR or to PNET 5 MB - SR, respectively. The
      initial diagnostic assessments (imaging, staging, histology, and tumor biology) required for
      study entry are the same for both treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the LR-treatment arm is to confirm the high rate of event-free survival in
      patients between the ages of 3 to 5 years and less than 22, with 'standard risk'
      medulloblastoma with a low-risk biological profile. Patients eligible for the study will be
      those with non-metastatic medulloblastoma (by CSF cytology and centrally reviewed MRI
      imaging) at diagnosis and low-risk biological profile, defined as ß-catenin nuclear
      immuno-positivity by immuno-histochemistry (IHC). Patients will have undergone total or
      near-total tumour resection and will receive conventionally fractionated (once a day)
      radiotherapy with a dose of 54 Gy to the primary tumor and 18.0 Gy to the craniospinal axis.
      Following radiotherapy, patients will receive a reduced-intensity chemotherapy with a total
      of 6 cycles of chemotherapy consisting of 3 courses of cisplatin, CCNU and vincristine
      alternating with 3 courses of cyclophosphamide and vincristine.

      The aim of the SR-arm is to test whether concurrent carboplatin during radiotherapy followed
      by 8 cycles of maintenance chemotherapy in patients with 'standard risk' medulloblastoma with
      an average-risk biological profile may improve outcome. Patients eligible for the study will
      be those with non-metastatic medulloblastoma (by CSF cytology and centrally reviewed MRI
      imaging) at diagnosis and average-risk biological profile, defined as ß-catenin nuclear
      immuno-negativity by IHC. Patients will have undergone total or near-total tumour resection
      and will receive conventionally fractionated (once a day) radiotherapy with a dose of 54 Gy
      to the primary tumor and 23.4 Gy to the craniospinal axis. Following radiotherapy, patients
      will receive a modified-intensity chemotherapy with a total of 8 cycles of chemotherapy
      consisting of 4 courses of cisplatin, CCNU and vincristine alternating with 4 courses of
      cyclophosphamide and vincristine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Event-Free Survival (EFS)</measure>
    <time_frame>LR-arm after 9 years, SR-arm after 105 events (approx. 10 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of relapse</measure>
    <time_frame>10 years</time_frame>
    <description>Defined in 5 categorical variables:
no relapse, local relapse, distant relapse, local and distant relapse, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late effects of therapy on endocrine function</measure>
    <time_frame>10 years</time_frame>
    <description>measured as
subfertility (FSH &gt; 15 IU/L)
endocrine deficits (hormone supplementation necessary)
growth retardation (calculated as the difference in height standard deviation score from diagnose) 2 and 5 years after diagnosis and age of 18 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late effects of therapy on audiology</measure>
    <time_frame>8 years</time_frame>
    <description>measured on audiogram performed 2 years after diagnosis, grading according to Chang ototoxicity grading (Chang and Chinosornvatana 2010)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late effects of therapy on neurology</measure>
    <time_frame>10 years</time_frame>
    <description>Measured as
presence, duration, and therapy of hydrocephalus symptoms (pre- and post-operatively)
presence of posterior fossa syndrome (cerebellar mutism survey after surgery, before radiotherapy)
cerebellar symptoms (brief ataxia rating scales 2 and 5 years after diagnosis and age of 18 years)
presence of symptoms for brain nerve dysfunction (2 and 5 years after diagnosis and age of 18 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late effects of therapy on quality of survival</measure>
    <time_frame>10 years</time_frame>
    <description>measured with standardized questionnaires/ scores:
HUI3 (health status)
BRIEF (executive functions)
SDQ (behavioural outcome)
PedsQL (quality of life)
QLQ-C30 (quality of life)
MEES (neurological function, educational provision)
MFI (fatigue) 2 and 5 years after diagnosis and age of 18 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of carboplatin treatment</measure>
    <time_frame>approx. 7 years</time_frame>
    <description>measured as timely delivery of chemotherapy number of interruptions days during radiotherapy toxicities within 8 weeks after end of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual tumor</measure>
    <time_frame>6 years</time_frame>
    <description>measured by central MRI review postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukoencephalopathy grading</measure>
    <time_frame>8 years</time_frame>
    <description>measured 2 years after diagnosis grades 0, 1, 2, 3, 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Brain Tumors</condition>
  <arm_group>
    <arm_group_label>PNET 5 MB-LR (low-risk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNET 5 MB-SR (standard-risk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.
Total treatment duration is 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy without Carboplatin</intervention_name>
    <description>Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks
LR Arm after Amendment (Protocol version 11- 17 Nov 2014):
Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks</description>
    <arm_group_label>PNET 5 MB-LR (low-risk)</arm_group_label>
    <arm_group_label>PNET 5 MB-SR (standard-risk)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced-intensity maintenance chemotherapy</intervention_name>
    <description>Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.
Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.
Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.</description>
    <arm_group_label>PNET 5 MB-LR (low-risk)</arm_group_label>
    <other_name>Cisplatin</other_name>
    <other_name>Lomustin (CCNU)</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with Carboplatin</intervention_name>
    <description>Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.</description>
    <arm_group_label>PNET 5 MB-SR (standard-risk)</arm_group_label>
    <other_name>Carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance chemotherapy</intervention_name>
    <description>Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.
Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients).</description>
    <arm_group_label>PNET 5 MB-SR (standard-risk)</arm_group_label>
    <other_name>Cisplatin</other_name>
    <other_name>Lomustine (CCNU)</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age at diagnosis, at least 3 - 5 years (depending on the country) and less than 22
             years (LR-arm: less than 16 years). The date of diagnosis is the date on which surgery
             is undertaken.

          2. Histologically proven medulloblastoma, including the following subtypes, as defined in
             the WHO classification (2007): classic medulloblastoma, desmoplastic/nodular
             medulloblastoma. Pre-treatment central pathology review is considered mandatory.

          3. Standard-risk medulloblastoma, defined as;

               -  total or near total surgical resection with less than or equal to 1.5 cm2
                  (measured on axial plane) of residual tumour on early post-operative MRI, without
                  and with contrast, on central review;

               -  no central nervous system (CNS) metastasis on MRI (cranial and spinal) on central
                  review;

               -  no tumour cells on the cytospin of lumbar CSF

               -  no clinical evidence of extra-CNS metastasis; Patients with a reduction of
                  postoperative residual tumor through second surgery to less than or equal to 1.5
                  cm2 are eligible, if if timeline for start of radiotherapy can be kept.

          4. Submission of high quality biological material including fresh frozen tumor samples
             for the molecular assessment of biological markers (such as the assessment of
             myelocytomatosis oncogene (MYC) copy number status) in national biological reference
             centers. Submission of blood is mandatory for all patients, who agree on germline DNA
             studies. Submission of CSF is recommended.

          5. No amplification of MYC or MYCN (determined by FISH).

          6. For LR-arm: Low-risk biological profile, defined as WNT subgroup positivity. The WNT
             subgroup is defined by the presence of (i) ß-catenin mutation (mandatory testing), or
             (ii) ß-catenin nuclear immuno-positivity by IHC (mandatory testing) and ß-catenin
             mutation, or (iii) ß-catenin nuclear immuno-positivity by IHC and monosomy 6 (optional
             testing).

             For SR-arm: average-risk biological profile, defined as ß-catenin nuclear
             immuno-negativity by IHC (mandatory) and mutation analysis (optional).

          7. No prior therapy for medulloblastoma other than surgery.

          8. Radiotherapy aiming to start no more than 28 days after surgery. Foreseeable inability
             to start radiotherapy within 40 days after surgery renders patients ineligible for the
             study.

          9. Screening for the compliance with eligibility criteria should be completed, and
             patient should be included into the study within 28 days after first surgery (in case
             of second surgery within 35 days after first surgery). Inclusion of patients is not
             possible later than 40 days after first tumour surgery, or after start of
             radiotherapy.

         10. Common toxicity criteria (CTC) grades &lt; 2 for liver, renal, haematological function

         11. no significant sensorineural hearing deficit as defined by pure tone audiometry with
             bone conduction or air conduction and normal tympanogram showing no impairment ≥ 20
             decibel (dB) at 1-3 kilohertz (kHz). If performance of pure tone audiometry is not
             possible postoperatively, normal otoacoustic emissions are acceptable, if there is no
             history for hearing deficit.

         12. No medical contraindication to radiotherapy or chemotherapy, such as preexisting DNA
             breakage syndromes (e.g. Fanconi Anemia, Nijmegen breakage syndrome), Gorlin Syndrome
             or other reasons as defined by patient's clinician.

         13. No identified Turcot and Li Fraumeni syndrome.

         14. Written informed consent (and patient assent where appropriate) for therapy according
             to the laws of each participating country. Information must be provided to the patient
             on biological studies (tumour and germline), and written informed consent obtained of
             agreement for participation.

         15. National and local ethical committee approval according to the laws of each
             participating country (to include approval for biological studies).

        Exclusion Criteria:

          1. One of the inclusion criteria is lacking.

          2. Brainstem or supratentorial primitive neuro-ectodermal tumour.

          3. Atypical teratoid rhabdoid tumour.

          4. Medulloepithelioma; Ependymoblastoma

          5. Large-cell medulloblastoma, anaplastic medulloblastoma, or medulloblastoma with
             extensive nodularity (MBEN), centrally confirmed.

          6. Unfavourable or undeterminable biological profile, defined as amplification of MYC or
             MYCN, or MYC or MYCN or WNT subgroup status not determinable.

          7. Metastatic medulloblastoma (on CNS MRI and/or positive cytospin of postoperative
             lumbar CSF).

          8. Patient previously treated for a brain tumour or any type of malignant disease.

          9. DNA breakage syndromes (e.g. Fanconi anemia, Nijmegen breakage syndrome) or other, or
             identified Gorlin,Turcot, or Li Fraumeni syndrome.

         10. Patients who are pregnant.

         11. Female patients who are sexually active and not taking reliable contraception.

         12. Patients who cannot be regularly followed up due to psychological, social, familial or
             geographic reasons.

         13. Patients in whom non-compliance with toxicity management guidelines can be expected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Doz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Rutkowski, Prof. Dr. med.</last_name>
    <phone>+49-40-7410</phone>
    <phone_ext>58200</phone_ext>
    <email>r.rutkowski@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katja von Hoff, Dr. med.</last_name>
    <phone>+49-40-7410</phone>
    <phone_ext>53394</phone_ext>
    <email>k.von-hoff@uke.uni-hamburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Benesch, Dr.</last_name>
      <email>martin.benesch@klinikum-graz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Jacobs, Prof.</last_name>
      <email>; sandra2.jacobs@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaroslav Sterba, Prof.</last_name>
      <email>jsterb@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid Sehested, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Curie</name>
      <address>
        <city>Paris Cedex 05</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Doz, Prof. Dr.</last_name>
      <email>francois.doz@curie.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU-TOURS - Hôpital Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital NANCY-BRABOIS</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite Campus, University of Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vestische Kinder- und Jugendklinik, University Witten/Herdecke</name>
      <address>
        <city>Datteln</city>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum-Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt/Main</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Gießen and Marburg</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle/Saale</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Rutkowski, Prof.</last_name>
      <phone>+49-40-7410</phone>
      <phone_ext>58200</phone_ext>
      <email>s.rutkowski@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Angelika-Lautenschläger-Klinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Herdecke</name>
      <address>
        <city>Herdecke</city>
        <zip>58313</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Homburg/Saar</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UK-SH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Koblenz-Mayen</name>
      <address>
        <city>Koblenz</city>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln</name>
      <address>
        <city>Köln</city>
        <zip>50735</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital München, Dr. von Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing, Pediatric Hospital of Technical University</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cnopf'sche Kinderklinik</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Sankt Augustin</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS-Kliniken Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jane Pears, Dr.</last_name>
      <email>jane.pears@olchc.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Massimino, Dr.</last_name>
      <email>maura.massimino@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roel E Reddingius, Dr.</last_name>
      <email>r.reddingius@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Finn Wesenberg, Prof.</last_name>
      <email>finn.wesenberg@rigshospitalet.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Memorial Health Institute</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Perek, Dr.</last_name>
      <email>m.perek-polnik@czd.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital S.Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Joao Gil-da-Costa, Dr.</last_name>
      <email>mjgildacosta@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hospital Cruces Bilbao</name>
      <address>
        <city>Baracaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurora Navajas Guitierrez, Prof.</last_name>
      <email>anavjas@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barncancercentrum Drottning Silvias Barnochungdomssjukhus</name>
      <address>
        <city>Göteburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitta Lannering, Prof.</last_name>
      <email>birgitta.lannering@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Gerber, Dr.</last_name>
      <email>nicolas.gerber@kispi.uzh.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antony Michalski, Dr.</last_name>
      <email>antony.michalski@gosh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric brain tumor</keyword>
  <keyword>medulloblastoma</keyword>
  <keyword>event-free survival (EFS)</keyword>
  <keyword>progression-free survival (PFS)</keyword>
  <keyword>overall survival (OS)</keyword>
  <keyword>PNET</keyword>
  <keyword>posterior fossa</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>biological profile</keyword>
  <keyword>ß-catenin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

